Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs

Zhiwei Li; Jiaqi Bu; Xinyu Zhu; Hao Zhou; Kaiqun Ren; Paul Kim Ho Chu; Limin Li; Xiang Hu; Xiaofeng Ding

doi:10.1016/j.bioadv.2022.212761

Back

Shared by

Paul Kim Ho Chu

Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs

Article 2022 en

Authors

ZL
Zhiwei Li
JB
Jiaqi Bu
XZ
Xinyu Zhu

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2017

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Elizabeth Allen, Arnaud Jabouille, Lee B. Rivera, Inge Lodewijckx, Rindert Missiaen, Veronica Steri, Kevin Feyen, Jaime Tawney, Douglas Hanahan, Iacovos P. Michael, Gabriele Bergers

Article2020

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Masatoshi Kudo

Editorial Material2019

Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies

Masatoshi Kudo

Article2010

Stimulation of anti-tumor immunity by photodynamic therapy

Paweł Mróz, Javad T. Hashmi, Ying‐Ying Huang, Norbert Lange, Michael R Hamblin

Article2020

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Masatoshi Kudo